RNS Number : 7658R
Shield Therapeutics PLC
08 July 2022

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Notice of General Meeting

London, UK, 8 July 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces that the following documents have now been sent to shareholders:

- Notice of General Meeting ("General Meeting") 27 July 2022

In accordance with AIM Rule 26, these documents are also available to view on the Company's website: https://www.shieldtherapeutics.com/corporate-documents/

We welcome shareholders who are able to join us at the General Meeting. The General Meeting will be held at 3pm on 27 July 2022 or, if earlier, as soon as the Annual General Meeting has completed which is due to be held at 2pm on 27 July 2022 at the offices of Shield Therapeutics plc, Northern Design Centre, Baltic Business Quarter, Gateshead Quays, England NE8 3DF. Should restrictions be imposed that prevent these Meetings from being held in person the Company has made provisions for the Meetings to be held both virtually and electronically and details will be provided to shareholders. The General Meeting is being held for the purpose of considering and, if thought fit, passing the Resolutions for the authorities required in order to agree to grant the conversion rights pursuant to a shareholder loan to be granted by AOP Orphan International AG.

If you wish to attend the General Meeting in your capacity as a shareholder, please bring proof of shareholding or if shares are held through a nominee account, a letter of representation, to facilitate your entry to the Meeting.

The Company will provide a facility for shareholders to join the General Meeting online and telephonically. In order to facilitate the process, the Board would request that shareholders register for the meeting before 2.00pm (BST) on 25 July 2022.

To register for dial-in details please contact Walbrook PR via email at shield@walbrookpr.com or call +44 (0)20 7933 8787.

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO

Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900

Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks +44 (0)20 7220 0500

Financial PR & IR Advisor
Walbrook PR

Paul McManus/Lianne Applegarth/Alice Woodings — +44 (0)20 7933 8780 or shield@walbrookpr.com

Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly — +1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGFLFETDAIDIIF